PURPOSE: Our previously reported therapeutic synergy between naturally occurring seleno-amino acid methylselenocysteine (MSC) and anticancer drugs could not be shown in vitro. Studies were carried out to investigate the potential role of MSC-induced tumor vascular maturation and increased drug delivery in the observed therapeutic synergy in vivo. EXPERIMENTAL DESIGN: Mice bearing s.c. FaDu human head and neck squamous cell carcinoma xenografts were treated with MSC (0.2 mg/d x 14 days orally). Changes in microvessel density (CD31), vascular maturation (CD31/alpha-smooth muscle actin), perfusion (Hoechst 33342/DiOC7), and permeability (dynamic contrast-enhanced magnetic resonance imaging) were determined at the end of the 14-day treatment period. Additionally, the effect of MSC on drug delivery was investigated by determining intratumoral concentration of doxorubicin using high-performance liquid chromatography and fluorescence microscopy. RESULTS: Double immunostaining of tumor sections revealed a marked reduction ( approximately 40%) in microvessel density accompanying tumor growth inhibition following MSC treatment along with a concomitant increase in the vascular maturation index ( approximately 30% > control) indicative of increased pericyte coverage of microvessels. Hoechst 33342/DiOC7 staining showed improved vessel functionality, and dynamic contrast-enhanced magnetic resonance imaging using the intravascular contrast agent, albumin-GdDTPA, revealed a significant reduction in vascular permeability following MSC treatment. Consistent with these observations, a 4-fold increase in intratumoral doxorubicin levels was observed with MSC pretreatment compared with administration of doxorubicin alone. CONCLUSION: These results show, for the first time, the antiangiogenic effects of MSC results in tumor growth inhibition, vascular maturation in vivo, and enhanced anticancer drug delivery that are associated with the observed therapeutic synergy in vivo.
PURPOSE: Our previously reported therapeutic synergy between naturally occurring seleno-amino acid methylselenocysteine (MSC) and anticancer drugs could not be shown in vitro. Studies were carried out to investigate the potential role of MSC-induced tumor vascular maturation and increased drug delivery in the observed therapeutic synergy in vivo. EXPERIMENTAL DESIGN:Mice bearing s.c. FaDu human head and neck squamous cell carcinoma xenografts were treated with MSC (0.2 mg/d x 14 days orally). Changes in microvessel density (CD31), vascular maturation (CD31/alpha-smooth muscle actin), perfusion (Hoechst 33342/DiOC7), and permeability (dynamic contrast-enhanced magnetic resonance imaging) were determined at the end of the 14-day treatment period. Additionally, the effect of MSC on drug delivery was investigated by determining intratumoral concentration of doxorubicin using high-performance liquid chromatography and fluorescence microscopy. RESULTS: Double immunostaining of tumor sections revealed a marked reduction ( approximately 40%) in microvessel density accompanying tumor growth inhibition following MSC treatment along with a concomitant increase in the vascular maturation index ( approximately 30% > control) indicative of increased pericyte coverage of microvessels. Hoechst 33342/DiOC7 staining showed improved vessel functionality, and dynamic contrast-enhanced magnetic resonance imaging using the intravascular contrast agent, albumin-GdDTPA, revealed a significant reduction in vascular permeability following MSC treatment. Consistent with these observations, a 4-fold increase in intratumoral doxorubicin levels was observed with MSC pretreatment compared with administration of doxorubicin alone. CONCLUSION: These results show, for the first time, the antiangiogenic effects of MSC results in tumor growth inhibition, vascular maturation in vivo, and enhanced anticancer drug delivery that are associated with the observed therapeutic synergy in vivo.
Authors: Arup Bhattacharya; Károly Tóth; Richard Mazurchuk; Joseph A Spernyak; Harry K Slocum; Lakshmi Pendyala; Rami Azrak; Shousong Cao; Farukh A Durrani; Youcef M Rustum Journal: Clin Cancer Res Date: 2004-12-01 Impact factor: 12.531
Authors: L C Clark; G F Combs; B W Turnbull; E H Slate; D K Chalker; J Chow; L S Davis; R A Glover; G F Graham; E G Gross; A Krongrad; J L Lesher; H K Park; B B Sanders; C L Smith; J R Taylor Journal: JAMA Date: 1996-12-25 Impact factor: 56.272
Authors: Mukund Seshadri; Richard Mazurchuk; Joseph A Spernyak; Arup Bhattacharya; Youcef M Rustum; David A Bellnier Journal: Neoplasia Date: 2006-07 Impact factor: 5.715
Authors: Marwan G Fakih; Lakshmi Pendyala; Patrick F Smith; Patrick J Creaven; Mary E Reid; Vladimir Badmaev; Rami G Azrak; Joshua D Prey; David Lawrence; Youcef M Rustum Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: M-B Yin; Z-R Li; K Tóth; S Cao; F A Durrani; G Hapke; A Bhattacharya; R G Azrak; C Frank; Y M Rustum Journal: Oncogene Date: 2006-04-20 Impact factor: 9.867
Authors: Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff Journal: Clin Cancer Res Date: 2007-07-01 Impact factor: 12.531
Authors: Hyunki Kim; Guihua Zhai; Zhiyong Liu; Sharon Samuel; Nemil Shah; Emily E Helman; Joseph A Knowles; Cecil R Stockard; Naomi S Fineberg; William E Grizzle; Tong Zhou; Kurt R Zinn; Eben L Rosenthal Journal: Anticancer Drugs Date: 2011-10 Impact factor: 2.248
Authors: Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain Journal: Physiol Rev Date: 2011-07 Impact factor: 37.312
Authors: Arup Bhattacharya; Steve G Turowski; Ivan Dominguez San Martin; Ashwani Rajput; Youcef M Rustum; Robert M Hoffman; Mukund Seshadri Journal: Anticancer Res Date: 2011-02 Impact factor: 2.480
Authors: Andrew R Carson; Charles F McTiernan; Linda Lavery; Abigail Hodnick; Michelle Grata; Xiaoping Leng; Jianjun Wang; Xucai Chen; Ruth A Modzelewski; Flordeliza S Villanueva Journal: Ultrasound Med Biol Date: 2011-01-21 Impact factor: 2.998
Authors: Arup Bhattacharya; Károly Tóth; Farukh A Durrani; Shousong Cao; Harry K Slocum; Sreenivasulu Chintala; Youcef M Rustum Journal: Neoplasia Date: 2008-08 Impact factor: 5.715
Authors: Arup Bhattacharya; Károly Tóth; Arindam Sen; Mukund Seshadri; Shousong Cao; Farukh A Durrani; Erik Faber; Elizabeth A Repasky; Youcef M Rustum Journal: Clin Colorectal Cancer Date: 2009-07 Impact factor: 4.481
Authors: Margaret Folaron; James Kalmuk; Jaimee Lockwood; Costakis Frangou; Jordan Vokes; Steven G Turowski; Mihai Merzianu; Nestor R Rigual; Maureen Sullivan-Nasca; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh; Mukund Seshadri Journal: Oral Oncol Date: 2013-07-23 Impact factor: 5.337